Should I buy or sell Elevation Oncology stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Elevation Oncology in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ELEV shares. View ELEV analyst ratings or view top-rated stocks .

What is Elevation Oncology's stock price target for 2024?

5 Wall Street analysts have issued twelve-month price targets for Elevation Oncology's stock. Their ELEV share price targets range from $6.00 to $8.00. On average, they anticipate the company's share price to reach $7.25 in the next twelve months. This suggests a possible upside of 90.8% from the stock's current price. View analysts price targets for ELEV or view top-rated stocks among Wall Street analysts .

How have ELEV shares performed in 2024?

Elevation Oncology's stock was trading at $0.5370 at the beginning of the year. Since then, ELEV stock has increased by 607.6% and is now trading at $3.80. View the best growth stocks for 2024 here .

Are investors shorting Elevation Oncology?

Elevation Oncology saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 5,010,000 shares, an increase of 8.2% from the March 15th total of 4,630,000 shares. Based on an average daily volume of 3,060,000 shares, the short-interest ratio is presently 1.6 days. Currently, 12.6% of the company's shares are short sold. View Elevation Oncology's Short Interest .

When is Elevation Oncology's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our ELEV earnings forecast .

How were Elevation Oncology's earnings last quarter?

Elevation Oncology, Inc. (NASDAQ:ELEV) released its quarterly earnings data on Wednesday, March, 6th. The company reported ($0.19) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.21) by $0.02.

When did Elevation Oncology IPO?

Elevation Oncology (ELEV) raised $1 billion in an initial public offering on Friday, June 25th 2021. The company issued 63,000,000 shares at $15.00-$17.00 per share.

How do I buy shares of Elevation Oncology?

Shares of ELEV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

Positive News SentimentPositive News

NASDAQ:ELEV

Elevation Oncology (ELEV) Stock Price, News & Analysis

→ Secret Bull Market Starts in This Unusual Sector (From Altimetry) (Ad)

Free ELEV Stock Alerts

$3.80

-0.21 (-5.24%)

(As of 04/19/2024 ET)

Compare

Today's Range: $3.75
▼
$4.07
50-Day Range: $2.56
▼
$5.17
52-Week Range: $0.36
▼
$5.89

Volume: 990,269 shs
Average Volume: 839,462 shs
Market Capitalization: $184.87 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $7.25

Get Elevation Oncology alerts:

Elevation Oncology MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 90.8% Upside
$7.25 Price Target
Short Interest: Bearish
12.58% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($0.87) to ($0.78) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.55 out of 5 stars

Medical Sector

609th out of 911 stocks

Biological Products, Except Diagnostic Industry

103rd out of 152 stocks

3.5

Analyst's Opinion

Consensus Rating
Elevation Oncology has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Elevation Oncology has only been the subject of 3 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
12.58% of the float of Elevation Oncology has been sold short.
Short Interest Ratio / Days to Cover
Elevation Oncology has a short interest ratio ("days to cover") of 1.6, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Elevation Oncology has recently increased by 8.21%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Elevation Oncology does not currently pay a dividend.
Dividend Growth
Elevation Oncology does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ELEV.

3.3

News and Social Media Coverage

News Sentiment
Elevation Oncology has a news sentiment score of 1.95. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.51 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for Elevation Oncology this week, compared to 1 article on an average week.
Search Interest
Only 6 people have searched for ELEV on MarketBeat in the last 30 days. This is a decrease of -74% compared to the previous 30 days.
MarketBeat Follows
4 people have added Elevation Oncology to their MarketBeat watchlist in the last 30 days. This is an increase of 33% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Elevation Oncology insiders have not sold or bought any company stock.
Percentage Held by Insiders
14.90% of the stock of Elevation Oncology is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
83.70% of the stock of Elevation Oncology is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Elevation Oncology are expected to grow in the coming year, from ($0.87) to ($0.78) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Elevation Oncology is -2.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Elevation Oncology is -2.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Elevation Oncology has a P/B Ratio of 2.95. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Gold Safe Exchange

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

About Elevation Oncology Stock (NASDAQ:ELEV)

Elevation Oncology, Inc., an oncology company, focuses on the discovery and development of cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. The company's lead candidate is EO-3021, an antibody-drug conjugate designed to target Claudin 18.2, a clinically validated molecular target. Its EO-3021 selectively delivers a cytotoxic payload directly to cancer cells expressing Claudin 18.2. Elevation Oncology, Inc. has a license agreement with CSPC Megalith Biopharmaceutical Co., Ltd. to develop and commercialize EO-3021. The company was formerly known as 14ner Oncology, Inc. and changed its name to Elevation Oncology, Inc. in February 2020. The company was incorporated in 2019 and is based in New York, New York.

ELEV Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ELEV Stock News Headlines

April 10, 2024 | americanbankingnews.com

Elevation Oncology's (ELEV) Buy Rating Reaffirmed at HC Wainwright

April 10, 2024 | msn.com

Biologic drug-device combination immunotherapy for metastatic prostate cancer patients

April 20, 2024 | Crypto 101 Media (Ad)

SHOCKING Crypto Leak…

A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.

April 9, 2024 | markets.businessinsider.com

Promising Preclinical Data and Positive Phase 2 Results Bolster Buy Rating for Elevation Oncology

April 8, 2024 | finance.yahoo.com

Elevation Oncology Presents Preclinical Proof-of-Concept Data for HER3-ADC Program at AACR Annual Meeting 2024

March 28, 2024 | msn.com

Design for proposed southern Utah reservoir is poor and poses risk to public safety, geophysicist says

March 28, 2024 | msn.com

Melanoma: All about the risks, symptoms, and common myths

March 27, 2024 | msn.com

Up 825% So Far in 2024, Can This Penny Stock Go Any Higher?

April 20, 2024 | Crypto 101 Media (Ad)

SHOCKING Crypto Leak…

March 11, 2024 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Adaptimmune Therapeutics (ADAP), Elevation Oncology (ELEV) and AC Immune SA (ACIU)

March 9, 2024 | benzinga.com

Elevation Oncology Stock (NASDAQ:ELEV), Quotes and News Summary

March 8, 2024 | investorplace.com

All Three of Our Analysts Agree

March 7, 2024 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Elevation Oncology (ELEV) and OrthoPediatrics (KIDS)

March 7, 2024 | finance.yahoo.com

Elevation Oncology Inc (ELEV) Reports Financial Results for Q4 and Full Year 2023

March 6, 2024 | markets.businessinsider.com

Elevation Oncology, Inc. Q4 Loss decreases, beats estimates

March 6, 2024 | msn.com

ELEV Stock Earnings: Elevation Oncology Beats EPS for Q4 2023

March 6, 2024 | finance.yahoo.com

Elevation Oncology to Present Preclinical Proof-of-Concept Data for HER3-ADC Program at the American Association for Cancer Research (AACR) Annual Meeting 2024

March 6, 2024 | finance.yahoo.com

Elevation Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Achievements

March 5, 2024 | investorplace.com

Trim the Fat: 3 Overbought Stocks Poised for a Pullback

March 4, 2024 | finance.yahoo.com

Elevation Oncology Appoints Experienced Clinical Development Leaders Julie Cherrington, Ph.D. and Alan Sandler, M.D. to Board of Directors

March 2, 2024 | msn.com

JMP Securities Initiates Coverage of Elevation Oncology (ELEV) with Market Outperform Recommendation

March 1, 2024 | markets.businessinsider.com

Optimistic Buy Rating for Elevation Oncology on EO-3021’s Promising Clinical Advancements and Differentiation

February 29, 2024 | prnewswire.com

SHAREHOLDER ALERT: Kaskela Law LLC Announces Shareholder Investigation of Elevation Oncology (ELEV) and Encourages Investors to Contact the Firm

February 28, 2024 | finance.yahoo.com

Elevation Oncology to Participate in Upcoming Investor Conferences

February 28, 2024 | prnewswire.com

Elevation Oncology to Participate in Upcoming Investor Conferences

February 24, 2024 | msn.com

Elevation Oncology expands Phase I solid tumour trial to Japan

February 24, 2024 | msn.com

Elevation Oncology (ELEV) Price Target Increased by 31.03% to 6.46

See More Headlines

Receive ELEV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Elevation Oncology and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/06/2024
Today: 4/20/2024
Next Earnings (Estimated): 5/20/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Current Symbol: NASDAQ:ELEV
CUSIP: N/A
CIK: 1783032
Web: www.elevationoncology.com
Phone: 716-371-1125
Fax: N/A
Employees: 29
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $7.25
High Stock Price Target: $8.00
Low Stock Price Target: $6.00
Potential Upside/Downside: +90.8%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 5 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.53)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-45,700,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -72.76%
Return on Assets: -43.15%

Debt

Debt-to-Equity Ratio: 0.55
Current Ratio: 21.22
Quick Ratio: 21.22

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.29 per share
Price / Book: 2.95

Miscellaneous

Outstanding Shares: 48,650,000
Free Float: 41,402,000
Market Cap: $184.87 million
Optionable: Optionable
Beta: 1.34

12 Stocks Corporate Insiders are Abandoning

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

Dr. David Dornan Ph.D. (Age 46)
Chief Scientific Officer
Comp: $545.5k
Ms. Valerie Malyvanh Jansen M.D. (Age 46)
Ph.D., Chief Medical Officer
Comp: $641.53k
Mr. Joseph J. Ferra Jr. (Age 49)
CEO, President & Director
Comp: $391.52k
Ms. Tammy Furlong CPA
P.M.P., CFO & Secretary
Mr. Ryan Bloomer
Head of Tech Ops
Candice Masse
Senior Director of Corporate Communications & Investor Relations
Mr. Robert C. Yang
Vice President of Legal Affairs

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

ELEV Stock Analysis - Frequently Asked Questions

Should I buy or sell Elevation Oncology stock right now?: 5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Elevation Oncology in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ELEV shares.
View ELEV analyst ratings or view top-rated stocks.
What is Elevation Oncology's stock price target for 2024?: 5 Wall Street analysts have issued twelve-month price targets for Elevation Oncology's stock. Their ELEV share price targets range from $6.00 to $8.00. On average, they anticipate the company's share price to reach $7.25 in the next twelve months. This suggests a possible upside of 90.8% from the stock's current price.
View analysts price targets for ELEV or view top-rated stocks among Wall Street analysts.
How have ELEV shares performed in 2024?: Elevation Oncology's stock was trading at $0.5370 at the beginning of the year. Since then, ELEV stock has increased by 607.6% and is now trading at $3.80.
View the best growth stocks for 2024 here.
Are investors shorting Elevation Oncology?: Elevation Oncology saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 5,010,000 shares, an increase of 8.2% from the March 15th total of 4,630,000 shares. Based on an average daily volume of 3,060,000 shares, the short-interest ratio is presently 1.6 days. Currently, 12.6% of the company's shares are short sold.
View Elevation Oncology's Short Interest.

When is Elevation Oncology's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024.
View our ELEV earnings forecast.
How were Elevation Oncology's earnings last quarter?: Elevation Oncology, Inc. (NASDAQ:ELEV) released its quarterly earnings data on Wednesday, March, 6th. The company reported ($0.19) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.21) by $0.02.
When did Elevation Oncology IPO?: Elevation Oncology (ELEV) raised $1 billion in an initial public offering on Friday, June 25th 2021. The company issued 63,000,000 shares at $15.00-$17.00 per share.
How do I buy shares of Elevation Oncology?: Shares of ELEV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ELEV) was last updated on 4/20/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial